The Daily Chase: Investors wary of Rogers-Shaw deal; one-on-one with Mark Carney VIDEO SIGN OUT
Shares of Shaw Communications closed almost seven dollars below the $40.50 takeover price yesterday as investors signaled apprehension about the long and daunting road ahead for closing the deal with Rogers. And itâs easy to understand why after we heard former Wind Mobile CEO Anthony Lacavera flatly stated in his conversation with Greg Bonnell during The Close yesterday that âthis is really bad for the consumer â short, medium and long-term.â Shortly before that, former Industry Minister Tony Clement said governments have faced a âconstant problemâ in ensuring wireless spectrum auctions are structured to ensure lasting, sustainable competition. Weâll continue to probe those and other important issues surrounding this transaction.
TORONTO At age 70, retired nurse Donna Lessard can expect to be towards the front of the line for a COVID-19 vaccine when supply and distribution expands in coming months. But instead, she s opted for an unproven vaccine candidate she can have now a two-dose product by the Quebec City-based biopharmaceutical Medicago currently running Phase 2 clinical trials. Because the trials are blinded, the Montrealer doesn t know if last month she received a second dose of the prospective vaccine or a placebo, and may not know for a year well after most Canadians are expected to receive one of several licensed vaccines.
Cassandra Szklarski
Retired nurse Donna Lessard is shown in a recent handout photo provided by Lessard. THE CANADIAN PRESS/HO-Donna Lessard MANDATORY CREDIT February 07, 2021 - 4:00 AM
TORONTO - At age 70, retired nurse Donna Lessard can expect to be towards the front of the line for a COVID-19 vaccine when supply and distribution expands in coming months.
But instead, sheâs opted for an unproven vaccine candidate she can have now â a two-dose product by the Quebec City-based biopharmaceuticalMedicago currently running Phase 2 clinical trials.
Because the trials are blinded, the Montrealer doesnât know if last month she received a second dose of the prospective vaccine or a placebo, and may not know for a year â well after most Canadians are expected to receive one of several licensed vaccines.
Tuesday s analyst upgrades and downgrades - The Globe and Mail theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.